Study of BMS-936558 (Nivolumab) Compared to Docetaxel in Previously Treated Metastatic Non-squamous NSCLC

Phase 3

Completed

• Conditions: Non-Squamous Cell Non-small Cell Lung Cancer
• Interventions: Biological: Nivolumab; Drug: Docetaxel

• Registration Number: NCT01673867
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of the study is to compare the overall survival of BMS-936558 (Nivolumab) as compared with Docetaxel in subjects with non-squamous cell non-small cell lung cancer (NSCLC) after failure of prior platinum-based chemotherapy

Detailed Description

CheckMate 057: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 057

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations
|
Related News

Study Timeline

• Study First Submitted: 2012-08-24
• Study First Submitted QC: 2012-08-24
• Study First Posted: 2012-08-28
• Study Start: 2012-11-02
• Primary Completion: 2015-02-05
• Results First Submitted: 2016-01-29
• Results First Submitted QC: 2016-01-29
• Results First Posted: 2016-02-26
• Study Completion: 2021-12-17
• Status Verified: 2023-01
• Last Update Submitted: 2023-01-13
• Last Update Posted: 2023-02-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 582

Inclusion Criteria

• Men & women ≥18 years of age
• Subjects with histologically or cytologically-documented non-squamous cell NSCLC who present with Stage IIIB/IV disease or recurrent or progressive disease following multimodal therapy (radiation therapy, surgical resection, or definitive chemoradiation therapy for locally advanced disease) and who will receive study therapy as second or third line of treatment for advanced disease
• Disease recurrence or progression during/after one prior platinum doublet-based chemotherapy regimen for advanced or metastatic disease
• Measurable disease by Computed tomography (CT)/Magnetic resonance imaging (MRI) per RECIST 1.1 criteria
• Eastern Cooperative Oncology Group (ECOG) performance status ≤1
• A formalin fixed, paraffin-embedded (FFPE) tumor tissue block or unstained slides of tumor sample (archival or recent) must be available for biomarker evaluation. Specimens must be received by the central lab prior to randomization. Biopsy should be excisional, incisional or core needle. Fine needle aspiration is insufficient

Read More

Exclusion Criteria

• Subjects with untreated central nervous system (CNS) metastases are excluded. Subjects are eligible if CNS metastases are asymptomatic or treated and subjects are neurologically returned to baseline for at least 2 weeks prior to enrollment. In addition, subjects must be either off corticosteroids, or on a stable or decreasing dose of ≤10mg daily prednisone (or equivalent)
• Subjects with carcinomatous meningitis
• Subjects with active or recent history of known or suspected autoimmune disease. Subjects with Type 1 diabetes mellitus, hypothyroidism only requiring hormone replacement, or skin disorders (vitiligo, psoriasis, or alopecia) not requiring systemic treatment are permitted to enroll
• Subjects with a condition requiring systemic treatment with either corticosteroids or other immunosuppressive medications within 14 days of randomization
• Prior therapy with anti-programmed death-1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), anti-programmed cell death ligand 2 (anti-PD-L2), anti-cluster of differentiation 137 (anti-CD137), or anti-Cytotoxic T lymphocyte-associated antigen 4 (anti-CTLA-4) antibody (including Ipilimumab or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways)
• Prior treatment with Docetaxel
• Treatment with any investigational agent within 14 days of first administration of study treatment

Other protocol-defined inclusion/exclusion criteria apply

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Arm A: Nivolumab	Nivolumab	Nivolumab 3 mg/kg solution intravenously (IV) every 2 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.
Arm B: Docetaxel	Docetaxel	Docetaxel 75 mg/m\^2 concentrate for solution for intravenous infusion every 3 weeks until documented disease progression, discontinuation due to toxicity, withdrawal of consent or the study ends. Eligible patients may receive nivolumab at 480mg every 4 weeks until documented disease progression, discontinuation, withdrawal of consent or the study ends.

Primary Outcome Measures

Name	Time	Method
Overall Survival (OS) Time in Months for All Randomized Participants at Primary Endpoint	Randomization until 413 deaths, up to March 2015 (approximately 29 months)	Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. OS will be followed continuously while participants are on the study drug and every 3 months via in-person or phone contact after participants discontinue the study drug. Median and hazard ratio computed using Kaplan-Meier method.

Secondary Outcome Measures

Name	Time	Method
Percentage of Participants Experiencing Disease-Related Symptom Improvement by Week 12	Randomization to Week 12	Disease-related symptom improvement rate by Week 12 was defined as the percentage of randomized participants who had a 10 point or greater decrease from baseline in average symptom burden index score at any time between randomization and Week 12. The participant portion of the Lung Cancer Symptom Scale (LCSS) consisted of 6 symptom-specific questions that addressed cough, dyspnea, fatigue, pain, hemoptysis, and anorexia, plus 3 summary items on symptom distress, interference with activity level, and global health-related Quality of Life (QoL). The scores range from 0 to 100, with 0 representing the best possible score and 100 being the worst possible score. The average symptom burden index score at each assessment was defined as the mean of the 6 symptom-specific questions of the LCSS. 95% CIs were computed using Clopper-Pearson Method.
Objective Response Rate (ORR)	From randomization to date of objectively documented progression (up to approximately 110 months)	ORR was defined as the percentage of participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). BOR was defined as the best investigator-assessed response designation, recorded between the date of randomization and the date of objectively documented progression per Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) or the date of subsequent anti-cancer therapy (excluding on-treatment palliative radiotherapy of non-target bone lesions or Central Nervous System (CNS) lesions), whichever occurred first. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm. PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method.
Overall Survival (OS) by PD-L1 Expression at Baseline	From randomization to the date of death or last known date alive (up to approximately 110 months)	Overall survival was defined as the time from randomization to the date of death. A participant who has not died will be censored at last known date alive. Overall Survival time was measured in months for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay. Median computed using the Kaplan-Meier method.
Time To Objective Response (TTOR)	From randomization to the date of first confirmed response (up to approximately 110 months)	Time to Objective Response for participants demonstrating a response (either CR or PR) was defined as the time from the date of randomization to the date of the first confirmed response. CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters.
Duration of Objective Response (DOOR)	From randomization to date of first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 110 months)	DOR was defined as the time from the date of first confirmed response to the date of the first documented tumor progression (per RECIST v1.1), as determined by the investigator, or death due to any cause, whichever occurred first. DOR was evaluated only for confirmed responders (i.e. participants with confirmed CR or PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. Participants who neither progressed nor died were censored on the date of their last evaluable tumor assessment. Median computed using Kaplan-Meier method.
Progression-Free Survival (PFS)	From randomization to first confirmed response to the date of the first documented tumor progression or death due to any cause, whichever occurred first (up to approximately 110 months)	PFS was defined as the time from randomization to the date of the first documented tumor progression (per RECIST 1.1) or death due to any cause. Participants who died without a reported prior progression were considered to have progressed on the date of their death. Progression will be assessed every 6 weeks (from the first on-study radiographic assessment) until disease progression is noted. Progressive disease was defined as least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered progression. Median computed using the Kaplan-Meier method.
Objective Response Rate (ORR) by PD-L1 Expression at Baseline	From randomization to date of objectively documented progression (up to approximately 110 months)	ORR was defined as the percentage of all randomized participants whose Best Overall Response (BOR) was a confirmed Complete Response (CR) or Partial Response (PR). CR = Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \< 10 mm.; PR = At least a 30% decrease in the sum of diameters of target lesions, taking, as reference, the baseline sum diameters. CR+PR, confidence interval based on the Clopper and Pearson method. ORR was reported for all randomized participants grouped by their baseline PD-L1 expression level. PD-L1 expression in participants was defined as the percent of disease tumor cells demonstrating plasma membrane PD-L1 staining of any intensity using an immunohistochemistry (IHC) assay.

Trial Locations

Locations (87)

Local Institution - 0035; 🇺🇸 Sayre, Pennsylvania, United States

Local Institution - 0054; 🇧🇷 Salvador, Bahia, Brazil

Local Institution - 0033; 🇺🇸 Dallas, Texas, United States

The Johns Hopkins University; 🇺🇸 Baltimore, Maryland, United States

Swedish Cancer Institute; 🇺🇸 Seattle, Washington, United States

Local Institution - 0026; 🇺🇸 Cincinnati, Ohio, United States

Local Institution - 0028; 🇺🇸 Nashville, Tennessee, United States

Vanderbilt University Medical Center; 🇺🇸 Nashville, Tennessee, United States

San Francisco Oncology Associates; 🇺🇸 San Francisco, California, United States

Local Institution - 0019; 🇺🇸 Morgantown, West Virginia, United States

Local Institution - 0133; 🇨🇦 Edmonton, Alberta, Canada

Local Institution - 0031; 🇺🇸 Boston, Massachusetts, United States

Local Institution; 🇨🇭 Chur, Switzerland

Local Institution - 0025; 🇺🇸 Columbia, South Carolina, United States

Local Institution - 0141; 🇳🇴 Oslo, Norway

Local Institution - 0099; 🇷🇴 Bucuresti, Romania

Dartmouth-Hitchcock Medical Center; 🇺🇸 Lebanon, New Hampshire, United States

Local Institution - 0058; 🇨🇱 Santiago, Metropolitana, Chile

Local Institution - 0062; 🇷🇴 Timisoara, Romania

Local Institution - 0110; 🇨🇦 Rimouski, Quebec, Canada

Local Institution - 0138; 🇺🇸 Boston, Massachusetts, United States

Local Institution - 0010; 🇦🇷 Capital Federal, Buenos Aires, Argentina

Local Institution - 0124; 🇦🇷 Ciudad De Buenos Aires, Buenos Aires, Argentina

Local Institution - 0011; 🇦🇷 Buenos Aires, Argentina

Local Institution - 0012; 🇨🇱 Viña Del Mar, Valparaiso, Chile

Local Institution - 0107; 🇲🇽 Mexico, Distrito Federal, Mexico

Local Institution - 0131; 🇵🇪 Miraflores, Lima, Peru

Local Institution - 0072; 🇵🇱 Olsztyn, Poland

Local Institution - 0024; 🇺🇸 Chattanooga, Tennessee, United States

Local Institution - 0134; 🇨🇱 Santiago, Metropolitana, Chile

Local Institution - 0073; 🇵🇱 Krakow, Małopolskie, Poland

Local Institution - 0123; 🇷🇴 Cluj-Napoca, Romania

Local Institution - 0120; 🇷🇺 Moscow, Russian Federation

Local Institution - 0049; 🇵🇪 Lima, Peru

Local Institution - 0068; 🇵🇱 Gdansk, Poland

Local Institution - 0070; 🇵🇱 Warszawa, Poland

Local Institution - 0061; 🇷🇴 Iasi, Romania

Local Institution - 0080; 🇷🇺 St. Petersburg, Russian Federation

Local Institution - 0078; 🇷🇺 Moscow, Russian Federation

Local Institution - 0063; 🇷🇴 Craiova, Romania

Local Institution - 0084; 🇮🇹 Padova, Italy

Local Institution - 0121; 🇮🇹 Parma, Italy

Local Institution - 0030; 🇺🇸 Chicago, Illinois, United States

Local Institution - 0027; 🇺🇸 Durham, North Carolina, United States

Local Institution - 0008; 🇺🇸 Mineola, New York, United States

Local Institution - 0009; 🇺🇸 Duarte, California, United States

Northwest Georgia Oncology Center, P.C.; 🇺🇸 Marietta, Georgia, United States

Mayo Clinic Arizona; 🇺🇸 Scottsdale, Arizona, United States

Local Institution - 0042; 🇺🇸 San Diego, California, United States

Local Institution - 0020; 🇺🇸 New York, New York, United States

Local Institution - 0032; 🇺🇸 Houston, Texas, United States

St. Mary Medical Center; 🇺🇸 Langhorne, Pennsylvania, United States

Local Institution - 0007; 🇺🇸 Seattle, Washington, United States

Local Institution - 0125; 🇦🇷 La Rioja, Argentina

Local Institution - 0055; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Local Institution - 0086; 🇮🇹 Bologna, Italy

Local Institution - 0052; 🇧🇷 Barretos, Sao Paulo, Brazil

Local Institution - 0119; 🇫🇷 La Roche Sur Yon Cedex 9, France

Local Institution - 0112; 🇫🇷 Marseille Cedex 20, France

Local Institution - 0053; 🇧🇷 Porto Alegre, Rio Grande Do Sul, Brazil

Local Institution - 0113; 🇫🇷 Lyon Cedex 08, France

Local Institution - 0051; 🇧🇷 Rio De Janeiro, Brazil

Local Institution - 0077; 🇨🇱 Santiago, Metropolitana, Chile

Local Institution - 0122; 🇮🇹 Bergamo, Italy

Local Institution - 0048; 🇵🇪 Lima, Peru

Local Institution - 0088; 🇮🇹 Ravenna, Italy

Local Institution - 0074; 🇭🇺 Budapest, Hungary

Local Institution - 0114; 🇫🇷 Rennes Cedex 9, France

Local Institution - 0108; 🇲🇽 Mexico, Distrito Federal, Mexico

Local Institution - 0050; 🇵🇪 Arequipa, Peru

Local Institution - 0079; 🇷🇺 Moscow, Russian Federation

Local Institution - 0082; 🇮🇹 Siena, Italy

Local Institution - 0067; 🇵🇱 Szczecin, Poland

Local Institution - 0001; 🇪🇸 Sevilla, Spain

Local Institution - 0090; 🇩🇪 Koeln, Germany

Local Institution - 0034; 🇺🇸 Tampa, Florida, United States

Local Institution - 0085; 🇮🇹 Milano, Italy

Local Institution - 0040; 🇺🇸 Boston, Massachusetts, United States

Local Institution - 0057; 🇦🇷 Capital Federal, Buenos Aires, Argentina

Local Institution - 0056; 🇧🇷 Fortaleza, Ceara, Brazil

Local Institution - 0018; 🇨🇿 Praha 8, Czechia

Local Institution - 0083; 🇮🇹 Perugia, Italy

Local Institution - 0087; 🇮🇹 Meldola (fc), Italy

Fox Chase Cancer Center; 🇺🇸 Philadelphia, Pennsylvania, United States

Yale University; 🇺🇸 New Haven, Connecticut, United States

Local Institution - 0041; 🇺🇸 Kennewick, Washington, United States

Local Institution - 0043; 🇭🇰 Hong Kong, Hong Kong